WO2002006313A2 - Regulation of human glutamate receptor delta-1 subunit - Google Patents
Regulation of human glutamate receptor delta-1 subunit Download PDFInfo
- Publication number
- WO2002006313A2 WO2002006313A2 PCT/EP2001/008102 EP0108102W WO0206313A2 WO 2002006313 A2 WO2002006313 A2 WO 2002006313A2 EP 0108102 W EP0108102 W EP 0108102W WO 0206313 A2 WO0206313 A2 WO 0206313A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subunit
- glutamate receptor
- polypeptide
- receptor delta
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to the regulation of human glutamate-like receptors to provide therapeutic effects.
- glutamate receptor classification schemes are based on pharmacological criteria which serve to define five receptor subtypes or classes: those activated by N-methyl-D-aspartic acid (NMD A), kainic acid (KA), ⁇ -amino-3-hydroxy-5-methyl- isoxazole-4-propionic acid (AMP A, formally called the quisqualic acid or QUIS receptor), 2-amino-4-phosphonobutyric acid (AP4 or APB), and 1-amino-cyclo- pentyl-l,3-dicarboxylic acid (ACPD).
- NMD A N-methyl-D-aspartic acid
- KA kainic acid
- AMP A ⁇ -amino-3-hydroxy-5-methyl- isoxazole-4-propionic acid
- AP4 or APB 2-amino-4-phosphonobutyric acid
- ACPD 1-amino-cyclo- pentyl-l,3-dicarboxylic acid
- ACPD receptor subtype which has the properties of a metabotropic receptor.
- This class of glutamate receptors alters synaptic physiology via GTP-binding proteins and the second messengers diacylglycerol and inositol 1,4,5-triphosphate (Gundersen et al., Proc. R. Soc. London Ser. B 221, 127, 1984; Sladeczek et al, Nature 317, 111, 1985; Nicoletti et al, J. Neurosci. 6, 1905, 1986; Sugiyama et al, Nature 325, 531, 1987).
- Yet another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation.
- a test compound is contacted with a glutamate receptor delta- 1 subunit polypeptide comprising an amino acid sequence selected from the group consisting of: amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 5; the amino acid sequence shown in SEQ ID NO: 5; amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 6; the amino acid sequence shown in SEQ ID NO: 6; amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 7; the amino acid sequence shown in SEQ ID NO:7; amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 8; and the amino acid sequence shown in SEQ ID NO: 8.
- a test compound which binds to the glutamate receptor delta- 1 subunit polypeptide is thereby identified as a potential agent for decreasing extracellular matrix degradation.
- the agent can work by decreasing the activity of the glutamate receptor delta- 1 subunit.
- Another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation.
- a test compound is contacted with a polynucleotide encoding a glutamate receptor delta- 1 subunit polypeptide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of: nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 9; the nucleotide sequence shown in SEQ ID NO: 9; nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 10; the nucleotide sequence shown in SEQ ID NO: 10; nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 11 ; the nucleotide sequence shown in SEQ ID NO:l 1 nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 12; and the nucleotide sequence shown in SEQ ID NO: 12.
- a test compound which binds to the polynucleotide is identified as a potential agent for decreasing extracellular matrix degradation.
- the agent can work by decreasing the amount of the glutamate receptor delta- 1 subunit through interacting with the glutamate receptor delta- 1 subunit mRNA.
- a test compound is contacted with a glutamate receptor delta- 1 subunit polypeptide comprising an amino acid sequence selected from the group consisting of: amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 5; the amino acid sequence shown in SEQ ID NO: 5; amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 6; the amino acid sequence shown in SEQ ID NO: 6; amino acid sequences which are at least about 50% identical to the amino acid 5 sequence shown in SEQ ID NO: 7; the amino acid sequence shown in SEQ ID NO:7; amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 8; and the amino acid sequence shown in SEQ ID NO: 8. re
- a glutamate receptor delta- 1 subunit activity of the polypeptide is detected.
- a test compound which increases glutamate receptor delta- 1 subunit activity of the polypeptide relative to glutamate receptor delta- 1 subunit activity in the absence of the test compound is thereby identified as a potential agent for increasing 15 extracellular matrix degradation.
- a test compound which decreases glutamate receptor delta- 1 subunit activity of the polypeptide relative to glutamate receptor delta- 1 subunit activity in the absence of the test compound is thereby identified as a potential agent for decreasing extracellular matrix degradation.
- a test compound is contacted with a glutamate receptor delta- 1 subunit product of a polynucleotide which comprises a nucleotide sequence selected from the group consisting of: nucleotide sequences which are at least about 50% identical to the nucleotide 5 sequence shown in SEQ ID NO: 9; the nucleotide sequence shown in SEQ ID NO: 9; nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 10; the nucleotide sequence shown in SEQ ID NO: 10; 0 nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 11 ; and the nucleotide sequence shown in SEQ ID NO:l 1 ; nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 12; and the nucleotide sequences
- a test compound which binds to the glutamate receptor delta- 1 subunit product is thereby identified as a potential agent for decreasing extracellular matrix degradation.
- Still another embodiment of the invention is a method of reducing extracellular matrix degradation.
- a cell is contacted with a reagent which specifically binds to a polynucleotide encoding a glutamate receptor delta- 1 subunit polypeptide or the product encoded by the polynucleotide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of: nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 9; the nucleotide sequence shown in SEQ ID NO: 9; nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 10; the nucleotide sequence shown in SEQ ID NO: 10; nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 11; the nucleotide sequence shown in SEQ ID NO:l 1; nucleotide sequences
- Glutamate receptor delta- 1 subunit activity in the cell is thereby decreased.
- the invention thus provides reagents and methods for regulating a human glutamate receptor delta- 1 subunit.
- Such reagents and methods can be used ter alia, to treat or prevent epilepsy, schizophrenia and other mood disorders, neurodegenerative diseases such as Huntington's disease and Alzheimer's disease, ischemia, pain, benign prostate hyperplasia and urinary incontinence.
- Fig. 1 shows the amino acid sequence of the rattus norvegicus Sprague-
- Dawley glutamate receptor delta- 1 subunit identified with the Accesseion No. U08255 (SEQ ED NO: 1).
- Fig. 2 shows the DNA-sequence of a glutamate receptor delta- 1 subunit polypeptide (SEQ ID NO:2).
- Fig. 3 shows the DNA-sequence of a glutamate receptor delta- 1 subunit polypeptide (SEQ ID NO:3).
- Fig. 4 shows the DNA-sequence of a glutamate receptor delta- 1 subunit polypeptide (SEQ ID NO:4).
- Fig. 5 shows the amino acid sequence of a glutamte receptor delta 1 subunit polypeptide (SEQ ID NO:5).
- Fig. 6 shows the amino acid sequence of a glutamte receptor delta 1 subunit polypeptide (SEQ ID NO:6).
- Fig. 7 shows the amino acid sequence of a glutamte receptor delta 1 subunit polypeptide (SEQ ID NO:7).
- Fig. 8 shows the amino acid sequence of a glutamte receptor delta 1 subunit polypeptide (SEQ ID NO:8).
- Fig. 9 shows the DNA-sequence of a glutamte receptor delta 1 subunit polypeptide (SEQ ID NO:9).
- Fig. 10 shows the DNA-sequence of a glutamte receptor delta 1 subunit polypeptide (SEQ ID NO: 10).
- Fig. 11 shows the DNA-sequence of a glutamte receptor delta 1 subunit polypeptide (SEQ ID NO: 11).
- Fig. 12 shows the exons which encompass the first approximately 190 amino acids of glutamate receptor delta-1 subunit polypeptide.
- Fig. 13 shows the protein sequences of glutamate receptor delta- 1 subunit polypeptide.
- Fig. 14 shows the BLASTP alignment of glutamate receptor delta- 1 subunit polypeptide with the rat protein identified with GenBank Accession No. U08255.
- Fig. 15 shows the DNA-sequence of a glutamte receptor delta 1 subunit polypeptide (SEQ ID NO: 12).
- the invention relates to an isolated polynucleotide encoding a glutamate" receptor delta- 1 subunit polypeptide and being selected from the group consisting of: a) a polynucleotide encoding a glutamate receptor delta- 1 subunit polypeptide comprising an amino acid sequence selected from the group consisting of: amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 5; the amino acid sequence shown in SEQ ID NO: 5; amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 6; the amino acid sequence shown in SEQ ID NO: 6; amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 7; the amino acid sequence shown in SEQ ID NO: 7; amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 8; and the amino acid sequence shown in SEQ ID NO: 8.
- glutamate receptor delta-1 subunit Previously identified glutamate receptor delta-1 subunit presently has the status of an orphan receptor. Villmann et al, Eur. J. Neurosci. 11, 11765-78, 1999. In mice, this receptor is expressed in inner hair cells and in type I and type II vestibular hair cells, suggestion a functional role in neurotransmission in hair cells. Saffieddine & Wenthold, J Neurosci. 17, 7523-31, 1999. It is believed that the human glutamate receptor delta-1 subunit can be used to develop treatments for various diseases, to develop diagnostic assays for these diseases, and to provide new tools for basic research especially in the fields of medicine and biology.
- the present invention can be used to develop new drugs to treat or prevent epilepsy, schizophrenia and other mood disorders, neurodegenerative diseases such as Huntington's disease and Alzheimer's disease, ischemia, pain, benign prostate hyperplasia and urinary incontinence.
- neurodegenerative diseases such as Huntington's disease and Alzheimer's disease
- ischemia ischemia
- pain benign prostate hyperplasia
- urinary incontinence Polypeptides
- Glutamate receptor delta-1 subunit variants which are biologically active, i.e., retain a ligand-binding function and/or a neurotransmission function, also are glutamate receptor delta-1 subunit polypeptides.
- glutamate receptor delta-1 subunit variants Preferably, naturally or non-naturally occurring glutamate receptor delta-1 subunit variants have amino acid sequences which are at least about 50, 55, 60, 65, 70, preferably about 75, 90, 96, 98, or 99% identical to an amino acid sequence shown in SEQ ID NOS:5, 6, 7, or 8.
- Percent identity between a putative glutamate receptor delta-1 subunit variant and an amino acid sequence of SEQ ID NOS:5, 6, 7, or 8 is determined with the Needleman/Wunsch algorithm (Needleman and Wunsch, J.Mol. Biol. 48; 443-453, 1970) using a Blosum62 matrix with a gap creation penalty of 8 and a gap extension penalty of 2 (S. Henikoff and J.G. Henikoff, Proc. Natl. Acad. Sci. USA 89:10915- 10919, 1992).
- Variations in percent identity can be due, for example, to amino acid substitutions, insertions, or deletions.
- Amino acid substitutions are defined as one for one amino acid replacements. They are conservative in nature when the substituted amino acid has similar structural and/or chemical properties. Examples of conservative replacements are substitution of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.
- Amino acid insertions or deletions are changes to or within an amino acid sequence. They typically fall in the range of about 1 to 5 amino acids.
- Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity of a glutamate receptor delta-1 subunit polypeptide can be found using computer programs well known in the art, such as
- Fusion proteins are useful for generating antibodies against glutamate " receptor delta-1 subunit amino acid sequences and for use in various assay systems. For example, fusion proteins can be used to identify proteins which interact with portions of a glutamate receptor delta-1 subunit polypeptide. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.
- a glutamate receptor delta-1 subunit fusion protein comprises two protein segments fused together by means of a peptide bond.
- the first protein segment comprises at least 5, 6, 8, 10, 25, or 50 or more contiguous amino acids of a glutamate receptor delta-1 subunit polypeptide.
- Contiguous amino acids for use in a fusion protein can be selected from the amino acid sequence shown in SEQ ID NOS:5, 6, 7, or 8 or from a biologically active variant of those sequences, such as those described above.
- the first protein segment also can comprise full-length glutamate receptor delta-1 subunit.
- the second protein segment can be a full-length protein or a protein fragment or polypeptide.
- Proteins commonly used in fusion protein construction include ⁇ - galactosidase, ⁇ -glucuronidase, green fluorescent protein (GFP), auto fluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT).
- epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV- G tags, and thioredoxin (Trx) tags.
- Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4
- a fusion protein also can be engineered to contain a cleavage site located between the glutamate receptor delta-1 subunit polypeptide-encoding sequence and the heterologous protein sequence, so that the glutamate receptor delta-1 subunit polypeptide can be cleaved and purified away from the heterologous moiety.
- a fusion protein can be synthesized chemically, as is known in the art.
- a fusion protein is produced by covalently linking two protein segments or by standard procedures in the art of molecular biology.
- Recombinant DNA methods can be used to prepare fusion proteins, for example, by making a DNA construct which comprises a coding sequence from NOS:2, 3, 4, 9, 10, and 11 in proper reading frame with nucleotides encoding the second protein segment and expressing the DNA construct in a host cell, as is known in the art.
- Many kits for constructing fusion proteins are available from companies such as Promega Corporation (Madison, WI), Stratagene (La Jolla, CA), CLONTECH (Mountain View, CA), Santa Cruz
- Species homologs of human glutamate receptor delta-1 subunit can be obtained using glutamate receptor delta-1 subunit polynucleotides (described below) to make suitable probes or primers for screening cDNA expression libraries from other species, such as mice, monkeys, or yeast, identifying cDNAs which encode homologs of glutamate receptor delta- 1 subunit, and expressing the cDNAs as is known in the art.
- glutamate receptor delta-1 subunit polynucleotides described below
- a glutamate receptor delta-1 subunit polynucleotide can be single- or double- stranded and comprises a coding sequence or the complement of a coding sequence for a glutamate receptor delta-1 subunit polypeptide. Coding sequences for a glutamate receptor delta-1 subunit polypeptide are shown in SEQ ID NOS:2, 3, 4, 9, 10, 11 and 12.
- nucleotide sequences encoding human glutamate receptor delta-1 subunit polypeptides, as well as homologous nucleotide sequences which are at least about
- polynucleotide sequences shown in SEQ ID NOS:2, 3, 4, 9, 10, 11 and 12 also are glutamate receptor delta-1 subunit polynucleotides.
- Percent sequence identity between the sequences of two polynucleotides is determined using computer programs such as ALIGN which employ the FASTA algorithm, using an affine gap search with a gap open penalty of -12 and a gap extension penalty of -2.
- cDNA Complementary DNA molecules, species homologs, and variants of glutamate receptor delta-1 subunit polynucleotides which encode biologically active glutamate receptor delta-1 subunit polypeptides also are glutamate receptor delta-1 subunit polynucleotides.
- Variants and homologs of the glutamate receptor delta-1 subunit polynucleotides described above also are glutamate receptor delta-1 subunit polynucleotides.
- homologous glutamate receptor delta-1 subunit polynucleotide sequences can be identified by hybridization of candidate polynucleotides to known glutamate receptor delta-1 subunit polynucleotides under stringent conditions, as is known in the art.
- homologous sequences can be identified which contain at most about 25-30% basepair mismatches. More preferably, homologous nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.
- Species homologs of the glutamate receptor delta-1 subunit polynucleotides disclosed herein also can be identified by making suitable probes or primers and screening cDNA expression libraries from other species, such as mice, monkeys, or yeast.
- Human variants of glutamate receptor delta-1 subunit polynucleotides can be identified, for example, by screening human cDNA expression libraries. II is well known that the T m of a double-stranded DNA decreases by 1-1.5 °C with every 1% decrease in homology (Bonner et al, J. Mol. Biol. 81, 123 (1973).
- Variants of human glutamate receptor delta-1 subunit polynucleotides or glutamate receptor delta-1 subunit polynucleotides of other species can therefore be identified by hybridizing a putative homologous glutamate receptor delta-1 subunit polynucleotide with a polynucleotide having a nucleotide sequence of SEQ ID NOS:2, 3, 4, 9, 10, 11 or 12 or the complements thereof to form a test hybrid.
- the melting temperature of the test hybrid is compared with the melting temperature of a hybrid comprising glutamate receptor delta-1 subunit polynucleotides having perfectly complementary nucleotide sequences, and the number or percent of basepair mismatches within the test hybrid is calculated.
- Nucleotide sequences which hybridize to glutamate receptor delta-1 subunit polynucleotides or their complements following stringent hybridization and/or wash conditions also are glutamate receptor delta-1 subunit polynucleotides.
- Stringent wash conditions are well known and understood in the art and are disclosed, for example, in Sambrook et al, MOLECULAR CLONING: A LABORATORY MANUAL, 2d ed., 1989, at pages 9.50-9.51.
- T m of a hybrid between a glutamate receptor delta-1 subunit polynucleotide having a nucleotide sequence shown in SEQ ID NOS:2, 3, 4, 9, 10, 11 and 12 or the complements thereof and a polynucleotide sequence which is at least about 50, 55, 60, 65, 70, preferably about 75, 90, 96, 98, or 99% identical to one of those nucleotide sequences can be calculated, for example, using the equation of Bolton and McCarthy, Proc. Natl. Acad. Sci. U.S.A. 48, 1390 (1962):
- Stringent wash conditions include, for example, 4X SSC at 65 °C, or 50% formamide, 4X SSC at 42 °C, or 0.5X SSC, 0.1% SDS at 65 °C.
- Highly stringent wash conditions include, for example, 0.2X SSC at 65 oC.
- a naturally occurring glutamate receptor delta-1 subunit polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids.
- Polynucleotides can be made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated glutamate receptor delta-1 subunit polynucleotides.
- restriction enzymes and probes can be used to isolate polynucleotide fragments which comprise glutamate receptor delta-1 subunit nucleotide sequences.
- Isolated polynucleotides are in preparations which are free or at least 70, 80, or 90% free of other molecules.
- Glutamate receptor delta-1 subunit cDNA molecules can be made with standard molecular biology techniques, using glutamate receptor delta-1 subunit mRNA as a template. Glutamate receptor delta-1 subunit cDNA molecules can thereafter be replicated using molecular biology techniques known in the art and disclosed in manuals such as Sambrook et al. (1989). An amplification technique, such as PCR, can be used to obtain additional copies of glutamate receptor delta-1 subunit polynucleotides using either human genomic DNA or cDNA as a template.
- glutamate receptor delta-1 subunit polynucleotides can be synthesized.
- the degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which will encode a glutamate receptor delta-1 subunit polypeptide having, for example, an amino acid sequence shown in SEQ ID NO:5, 6, 7, or 8 or a biologically active variant.
- the partial sequences of SEQ ID NOS:2, 3, 4, 9, 10, and 11 or their complements can be used to identify the corresponding full length gene from which they were derived.
- the partial sequences can be nick-translated or end-labeled with 32 P using polynucleotide kinase using labeling methods known to those with skill in the art (BASIC METHODS IN MOLECULAR BIOLOGY, Davis et al, eds., Elsevier Press, N.Y.,
- a lambda library prepared from human tissue can be screened directly with the labeled sequences of interest or the library can be converted en masse to pBluescript (Stratagene Cloning Systems, La Jolla, Calif. 92037) to facilitate bacterial colony screening (see Sambrook et al, 1989, pg. 1.20).
- pBluescript Stratagene Cloning Systems, La Jolla, Calif. 92037
- Positive cDNA clones are analyzed to determine the amount of additional sequence they contain using PCR with one primer from the partial sequence and the other primer from the vector.
- Clones with a larger vector-insert PCR product than the original partial sequence are analyzed by restriction digestion and DNA sequencing to determine whether they contain an insert of the same size or similar as the mRNA size determined from Northern blot Analysis.
- the complete sequence of the clones can be determined, for example after exonuclease III digestion
- PCR-based methods can be used to extend the nucleic acid sequences encoding the disclosed portions of human glutamate receptor delta-1 subunit to detect upstream sequences such as promoters and regulatory elements.
- restriction-site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, PCR Methods Applic. 2, 318-322, 1993). Genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.
- the method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.
- capture PCR involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom et al, PCR Methods Applic. 1, 111-119, 1991).
- multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.
- Randomly-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' non-transcribed regulatory regions.
- capillary electrophoresis systems can be used to analyze the size or confirm the nucleotide sequence of PCR or sequencing products.
- capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera.
- Output/light intensity can be converted to electrical signal using appropriate software (e.g. GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the entire process from loading of samples to computer analysis and electronic data display can be computer controlled.
- Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.
- Glutamate receptor delta-1 subunit polypeptides can be obtained, for example, by purification from human neuronal cells, by expression of glutamate receptor delta-1 subunit polynucleotides, or by direct chemical synthesis.
- Glutamate receptor delta-1 subunit polypeptides can be purified, for example, from human neuronal cells or cell lines or from cells which have been transfected with a glutamate receptor delta-1 subunit polynucleotide. Brain, particularly amygdala, corpus callosum, and hippocampus provide useful sources of human glutamate receptor delta-1 subunit polypeptides. A purified glutamate receptor delta-1 subunit polypeptide is separated from other compounds which normally associate with the glutamate receptor delta-1 subunit polypeptide in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art.
- a glutamate receptor delta-1 subunit polynucleotide can be inserted into an expression vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.
- Methods which are well known to those skilled in the art can be used to construct expression vectors containing sequences encoding glutamate receptor delta-1 subunit polypeptides and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described, for example, in Sambrook et al. (1989) and in Ausubel et al, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y, 1989.
- TMV TMV
- bacterial expression vectors e.g., Ti or pBR322 plasmids
- animal cell systems e.g., TMV, TMV, TMV, TMV, TMV, or with bacterial expression vectors (e.g., Ti or pBR322 plasmids), or animal cell systems.
- control elements or regulatory sequences are those non-translated regions of the vector — enhancers, promoters, 5' and 3' untranslated regions ⁇ which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity.
- any number of suitable transcription and translation elements including constitutive and inducible promoters, can be used.
- inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORTl plasmid (Life Technologies) and the like can be used.
- the baculovirus polyhedrin promoter can be used in insect cells.
- Promoters or enhancers derived from the genomes of plant cells e.g., heat shock, RUBISCO, and storage protein genes
- plant viruses e.g., viral promoters or leader sequences
- promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding a glutamate receptor delta-1 subunit polypeptide, vectors based on S V40 or EBV can be used with an appropriate selectable marker.
- a number of expression vectors can be selected depending upon the use intended for a glutamate receptor delta-1 subunit polypeptide. For example, when a large quantity of a glutamate receptor delta-1 subunit polypeptide is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multifunctional E. coli cloning and expression vectors such as BLUESCRIPT (Stratagene).
- a sequence encoding a glutamate receptor delta-1 subunit polypeptide can be ligated in frame with sequences for the amino-terminal Met and the subsequent 7 residues of ⁇ -galactosidase so that a hybrid protein is produced.
- pIN vectors Van Heeke &
- yeast Saccharomyces cerevisiae a number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH, can be used.
- constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH
- Plant and Insect Expression Systems the expression of sequences encoding glutamate receptor delta-1 subunit polypeptides can be driven by any of a number of promoters.
- viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV (Takamatsu, EMBO J. 6, 307-311, 1987).
- plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used (Coruzzi et al,
- An insect system also can be used to express a glutamate receptor delta-1 subunit polypeptide.
- Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in
- Sequences encoding glutamate receptor delta-1 subunit polypeptides can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of glutamate receptor delta-1 subunit polypeptides will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to infect & frugiperda cells or Trichoplusia larvae in which glutamate receptor delta-1 subunit polypeptides can be expressed (Engelhard et al, Proc. Nat. Acad. Sci. 91, 3224-3227, 1994). Mammalian Expression Systems
- a number of viral-based expression systems can be used to express glutamate receptor delta-1 subunit polypeptides in mammalian host cells.
- sequences encoding glutamate receptor delta-1 subunit polypeptides can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a non-essential El or E3 region of the viral genome can be used to obtain a viable virus which is capable of expressing a glutamate receptor delta-1 subunit polypeptide in infected host cells (Logan & Shenk, Proc. Natl. Acad.
- transcription enhancers such as the Rous sarcoma virus (RSV) enhancer can be used to increase expression in mammalian host cells.
- RSV Rous sarcoma virus
- HACs Human artificial chromosomes
- 6M to 10M are constructed and delivered to cells via conventional delivery methods (e.g., liposomes, polycationic amino polymers, or vesicles).
- Specific initiation signals also can be used to achieve more efficient translation of sequences encoding glutamate receptor delta-1 subunit polypeptides. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding a glutamate receptor delta-1 subunit polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used (see Scharf et al, Results Probl. Cell Differ. 20, 125-162, 1994).
- a host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed glutamate receptor delta-1 subunit polypeptide in the desired fashion.
- modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation.
- Post-translational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding, and/or function.
- Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.
- ATCC American Type Culture Collection
- Stable expression is preferred for long-term, high-yield production of recombinant proteins.
- cell lines which stably express glutamate receptor delta-1 subunit polypeptides can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a selective medium.
- the purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced glutamate receptor delta-1 subunit sequences.
- Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. See, for example, ANIMAL CELL CULTURE, R.I. Freshney, ed., 1986.
- herpes simplex virus thymidine kinase (Wigler et al, Cell 11, 213-31, 1977) and adenine phosphoribosyltransferase (Lowy et al, Cell 22, 817-23, 1980) genes which can be employed in tk ⁇ or aprf cells, respectively.
- antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection.
- dhfr confers resistance to methotrexate (Wigler et al, Proc. Natl. Acad. Sci.
- npt confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin et al, J. Mol. Biol. 150, 1-14, 1981), and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murray, 1992, supra). Additional selectable genes have been described. For example, trpB, allows cells to utilize indole in place of tryptophan; hisD, allows cells to utilize histinol in place of histidine (Hartman &
- Visible markers such as anthocyanins, ⁇ -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes et al, Methods Mol. Biol. 55, 121-131, 1995).
- marker gene expression suggests that a glutamate receptor delta-1 subunit polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding a glutamate receptor delta-1 subunit polypeptide is inserted within a marker gene sequence, transformed cells containing sequences which encode the glutamate receptor delta-1 subunit polypeptide can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a glutamate receptor delta-1 subunit polypeptide under the control of a single promoter.
- Expression of the marker gene in response to induction or selection usually indicates expression of a glutamate receptor delta-1 subunit polynucleotide.
- host cells which contain a glutamate receptor delta-1 subunit polynucleotide and which express a glutamate receptor delta-1 subunit polypeptide can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a polynucleotide sequence encoding a glutamate receptor delta-1 subunit polypeptide can be detected by DNA-DNA or
- Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding the glutamate receptor delta-1 subunit polypeptide to detect transformants which contain a glutamate receptor delta-1 subunit polynucleotide.
- a variety of protocols for detecting and measuring the expression of a glutamate receptor delta-1 subunit polypeptide, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS).
- ELISA enzyme-linked immunosorbent assay
- RIA radioimmunoassay
- FACS fluorescence activated cell sorting
- a two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on a glutamate receptor delta-1 subunit polypeptide can be used, or a competitive binding assay can be employed. These and other assays are described in Hampton et al, SEROLOGICAL METHODS: A LABORATORY MANUAL, APS Press, St. Paul, Minn.,
- Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding glutamate receptor delta-1 subunit polypeptides include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide.
- sequences encoding a glutamate receptor delta-1 subunit polypeptide can be cloned into a vector for the production of an mRNA probe.
- RNA probes are known in the art, are commercially available, and can be used to synthesize RNA probes in vitro by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.
- Host cells transformed with nucleotide sequences encoding a glutamate receptor delta-1 subunit polypeptide can be cultured under conditions suitable for the expression and recovery of the protein from cell culture.
- the polypeptide produced by a transformed cell can be secreted or contained intracellularly depending on the sequence and/or the vector used.
- expression vectors containing polynucleotides which encode glutamate receptor delta-1 subunit polypeptides can be designed to contain signal sequences which direct secretion of glutamate receptor delta-1 subunit polypeptides through a prokaryotic or eukaryotic cell membrane.
- purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension affinity purification system
- cleavable linker sequences such as those specific for Factor Xa or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the glutamate receptor delta-1 subunit polypeptide also can be used to facilitate purification.
- One such expression vector provides for expression of a fusion protein containing a glutamate receptor delta-1 subunit polypeptide and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMAC (immobilized metal ion affinity chromatography, as described in Porath et al., Prot. Exp. Purif.
- enterokinase cleavage site provides a means for purifying the glutamate receptor delta-1 subunit polypeptide from the fusion protein.
- Vectors which contain fusion proteins are disclosed in Kroll et al, DNA Cell Biol. 12, 441-453, 1993.
- Sequences encoding a glutamate receptor delta-1 subunit polypeptide can be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers et al, Nucl. Acids Res. Symp. Ser. 215-113, 1980; Horn et al. Nucl. Acids
- a glutamate receptor delta-1 subunit polypeptide itself can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques (Merrifield, J Am. Chem. Soc. 85, 2149-2154, 1963; Roberge et al, Science 269, 202-204, 1995). Protein synthesis can be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431 A Peptide Synthesizer (Perkin Elmer).
- fragments of glutamate receptor delta-1 subunit polypeptides can be separately synthesized and combined using chemical methods to produce a full-length molecule.
- the newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, PROTEINS: STRUCTURES AND MOLECULAR PRINCIPLES, WH Freeman and Co., New York, N.Y., 1983).
- the composition of a synthetic glutamate receptor delta-1 subunit polypeptide can be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, supra). Additionally, any portion of the amino acid sequence of the glutamate receptor delta-1 subunit polypeptide can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein. Production of Altered Polypeptides
- codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.
- nucleotide sequences disclosed herein can be engineered using methods generally known in the art to alter glutamate receptor delta-1 subunit polypeptide- encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA product.
- DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences.
- site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.
- An antibody which specifically binds to an epitope of a glutamate receptor delta-1 subunit polypeptide can be used therapeutically, as well as in immunochemical assays, such as Western blots, ELISAs, radioimmunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art.
- immunochemical assays such as Western blots, ELISAs, radioimmunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art.
- Various immunoassays can be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays are well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody which specifically binds to the immunogen.
- an antibody which specifically binds to a glutamate receptor delta-1 subunit polypeptide provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay.
- antibodies which specifically bind to glutamate receptor delta-1 subunit polypeptides do not detect other proteins in immunochemical assays and can immunoprecipitate a glutamate receptor delta-1 subunit polypeptide from solution.
- BCG Bacilli Calmette-Gueri ⁇
- Corynebacterium parvum axe especially useful.
- Monoclonal antibodies which specifically bind to a glutamate receptor delta-1 subunit polypeptide can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These techniques include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler et al, Nature 256, 495-497, 1985; Kozbor et al, J. Immunol. Methods 81, 31-42, 1985; Cote et al, Proc. Natl Acad. Sci. 80, 2026-2030, 1983; Cole et al, Mol. Cell Biol. 62, 109-120, 1984).
- chimeric antibodies the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used (Morrison et al, Proc. Natl Acad. Sci. 81, 6851-6855, 1984; Neuberger et al, Nature 312, 604-608, 1984; Takeda et al, Nature 314, 452-454, 1985).
- Monoclonal and other antibodies also can be "humanized” to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues.
- rodent antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grating of entire complementarity determining regions.
- humanized antibodies can be produced using recombinant methods, as described in GB2188638B.
- Antibodies which specifically bind to a glutamate receptor delta-1 subunit polypeptide can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. 5,565,332.
- a nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using standard recombinant D ⁇ A methods, and introduced into a cell to express the coding sequence, as described below.
- single-chain antibodies can be produced directly using, for example, filamentous phage technology (Verhaar et al, 1995, Int. J. Cancer 61, 497-501; ⁇ icholls et al, 1993, J. Immunol. Meth. 165, 81-91).
- Antibodies which specifically bind to glutamate receptor delta-1 subunit polypeptides also can be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi et al, Proc. Natl. Acad. Sci. 86, 3833-3837, 1989; Winter et al, Nature 349, 293-299, 1991).
- chimeric antibodies can be constructed as disclosed in WO 93/03151.
- Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, also can be prepared.
- Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which a glutamate receptor delta-1 subunit polypeptide is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.
- Antisense Oligonucleotides can be affinity purified by passage over a column to which a glutamate receptor delta-1 subunit polypeptide is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.
- Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of glutamate receptor delta-1 subunit gene products in the cell.
- Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters. See Brown, Meth. Mol. Biol. 20, 1-8, 1994; Sonveaux, Meth. Mol. Biol. 26, 1-72, 1994; Uhlmann et al,
- Modifications of glutamate receptor delta-1 subunit gene expression can be obtained by designing antisense oligonucleotides which will form duplexes to the control, 5', or regulatory regions of a glutamate receptor delta-1 subunit gene. Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons. Therapeutic advances using triplex
- An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.
- Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a glutamate receptor delta-1 subunit polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent glutamate receptor delta-1 subunit nucleotides, can provide sufficient targeting specificity for glutamate receptor delta-1 subunit mRNA.
- each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length.
- Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in length.
- One skilled in the art can easily use the calculated melting point of an antisense-sense pair to determine the degree of mismatching which will be tolerated between a particular antisense oligonucleotide and a particular glutamate receptor delta-1 subunit polynucleotide sequence.
- Antisense oligonucleotides can be modified without affecting their ability to hybridize to a glutamate receptor delta-1 subunit polynucleotide. These modifications can be internal or at one or both ends of the antisense molecule.
- internucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose.
- Modified bases and/or sugars such as arabinose instead of ribose, or a 3', 5 '-substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate group are substituted, also can be employed in a modified antisense oligonucleotide.
- modified oligonucleotides can be prepared by methods well known in the art. See, e.g., Agrawal et al, Trends Biotechnol 10, 152-158, 1992; Uhlmann et al, Chem. Rev. 90, 543-584, 1990; Uhlmann et al, Tetrahedron. Lett.
- Ribozymes are RNA molecules with catalytic activity. See, e.g., Cech, Science 236, 1532-1539; 1987; Cech, Ann. Rev. Biochem. 59, 543-568; 1990, Cech, Curr. Opin. Struct. Biol. 2, 605-609; 1992, Couture & Stinchcomb, Trends Genet. 12, 510-515,
- Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art (e.g., Haseloff et al, U.S. Patent 5,641,673).
- the mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences.
- the coding sequence of a glutamate receptor delta-1 subunit polynucleotide can be used to generate ribozymes which will specifically bind to mRNA transcribed from the glutamate receptor delta-1 subunit polynucleotide.
- Methods of designing and constructing ribozymes which can cleave RNA molecules in trans in a highly sequence specific manner have been developed and described in the art (see Haseloff et al. Nature 334, 585-591, 1988).
- the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme.
- the hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target (see, for example, Gerlach et «/., EP 321,201).
- Specific ribozyme cleavage sites within a glutamate receptor delta-1 subunit RNA target can be identified by scanning the glutamate receptor delta-1 subunit target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate glutamate receptor delta-1 subunit RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.
- the nucleotide sequence shown in SEQ ID NO:l and its complement provide sources of suitable hybridization region sequences. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target.
- the hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.
- Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease glutamate receptor delta-1 subunit expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art.
- a ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells.
- ribozymes can be engineered so that ribozyme expression will occur in response to factors which induce expression of a target gene. Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells. Screening Methods
- the invention provides methods for identifying modulators, i.e., candidate or test compounds which bind to glutamate receptor delta-1 subunit polypeptides or polynucleotides and/or have a stimulatory or inhibitory effect on, for example, expression or binding activity of the glutamate receptor delta-1 subunit polypeptide or polynucleotide, so as to regulate a biological function.
- Regulation of human glutamate receptor delta-1 subunit is useful, for example, for preventing or treating epilepsy, schizophrenia and other mood disorders, neurodegenerative diseases such as Huntington's disease and Alzheimer's disease, ischemia, pain, benign prostate hyperplasia and urinary incontinence.
- the invention provides assays for screening test compounds which bind to or modulate the binding activity of a glutamate receptor delta-1 subunit polypeptide or a glutamate receptor delta-1 subunit polynucleotide.
- a test compound preferably binds to a glutamate receptor delta-1 subunit polypeptide or polynucleotide.
- a test compound decreases a glutamate receptor delta-1 subunit ligand binding activity of a glutamate receptor delta-1 subunit polypeptide or expression of a glutamate receptor delta-1 subunit polynucleotide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the test compound.
- Test compounds can be pharmacologic agents already known in the art or can be compounds previously unknown to have any pharmacological activity.
- the compounds can be naturally occurring or designed in the laboratory. They can be isolated from microorganisms, animals, or plants, and can be produced recombinanfiy, or synthesized by chemical methods known in the art. If desired, test compounds can be obtained using any of the numerous combinatorial library methods known in the art, including but not limited to, biological libraries, spatially addressable parallel solid phase or solution phase libraries, synthetic library methods requiring deconvolution, the "one-bead one-compound” library method, and synthetic library methods using affinity chromatography selection.
- the biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer, or small molecule libraries of compounds. See Lam, Anticancer Drug Des. 12, 145, 1997.
- High Throughput Screening Test compounds can be screened for the ability to bind to glutamate receptor delta-1 subunit polypeptides or polynucleotides or to affect glutamate receptor delta-1 subunit ligand binding activity or glutamate receptor delta-1 subunit gene expression using high throughput screening.
- high throughput screening many discrete compounds can be tested in parallel so that large numbers of test compounds can be quickly screened.
- the most widely established techniques utilize 96-well microtiter plates. The wells of the microtiter plates typically require assay volumes that range from 50 to 500 ⁇ l.
- many instruments, materials, pipettors, robotics, plate washers, and plate readers are commercially available to fit the 96-well format.
- free format assays or assays that have no physical barrier between samples, can be used.
- an assay using pigment cells (melanocytes) in a simple homogeneous assay for combinatorial peptide libraries is described by Jayawickreme et al, Proc. Natl. Acad. Sci. U.S.A. 19, 1614-18 (1994).
- the cells are placed under agarose in petri dishes, then beads that carry combinatorial compounds are placed on the surface of the agarose.
- the combinatorial compounds are partially released the compounds from the beads. Active compounds can be visualized as dark pigment areas because, as the compounds diffuse locally into the gel matrix, the active compounds cause the cells to change colors.
- Chelsky "Strategies for Screening Combinatorial Libraries: Novel and Traditional Approaches," reported at the First Annual Conference of The Society for Biomolecular Screening in Philadelphia, Pa. (Nov. 7-10, 1995).
- Chelsky placed a simple homogenous enzyme assay for carbonic anhydrase inside an agarose gel such that the enzyme in the gel would cause a color change throughout the gel.
- beads carrying combinatorial compounds via a photolinker were placed inside the gel and the compounds were partially released by UV-light. Compounds that inhibited the enzyme were observed as local zones of inhibition having less color change.
- test samples are placed in a porous matrix.
- One or more assay components are then placed within, on top of, or at the bottom of a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support.
- a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support.
- the test compound is preferably a small molecule which binds to and occupies the active site of a glutamate receptor delta-1 subunit polypeptide, thereby making the active site inaccessible to substrate such that normal biological binding activity is prevented.
- small molecules include, but are not limited to, small peptides or peptide-like molecules.
- either the test compound or the glutamate receptor delta-1 subunit polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase.
- Detection of a test compound which is bound to the glutamate receptor delta-1 subunit polypeptide can then be accomplished, for example, by direct counting of radioemmission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product.
- binding of a test compound to a glutamate receptor delta-1 subunit polypeptide can be determined without labeling either of the interactants.
- a microphysiometer can be used to detect binding of a test compound with a glutamate receptor delta-1 subunit polypeptide.
- a microphysiometer e.g., CytosensorTM
- a microphysiometer is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS).
- Determining the ability of a test compound to bind to a glutamate receptor delta-1 subunit polypeptide also can be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) (Sjolander & Urbaniczky, Anal. Chem. 63, 2338-2345, 1991, and Szabo et al, Curr. Opin. Struct. Biol. 5, 699-705, 1995).
- BIA is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcoreTM). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.
- a glutamate receptor delta-1 subunit polypeptide can be used as a "bait protein" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent 5,283,317; Zervos et al, Cell 72, 223-232, 1993; Madura et al, J. Biol. Chem.
- the two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains.
- the assay utilizes two different DNA constructs. For example, in one construct a polynucleotide encoding a glutamate receptor delta-1 subunit polypeptide can be fused to a polynucleotide encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct a DNA sequence that encodes an unidentified protein (“prey" or "sample”) can be fused to a polynucleotide that codes for the activation domain of the known transcription factor.
- a DNA sequence that encodes an unidentified protein "prey" or "sample”
- the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ), which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein which interacts with the glutamate receptor delta-1 subunit polypeptide.
- a reporter gene e.g., LacZ
- glutamate receptor delta-1 subunit polypeptide or polynucleotide
- test compound can be bound to a solid support.
- Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads).
- Binding of the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined.
- a glutamate receptor delta-1 subunit polypeptide (or polynucleotide) or a test compound can be immobilized utilizing conjugation of biotin and streptavidin.
- Biotinylated glutamate receptor delta-1 subunit polypeptides, polynucleotides, or test compounds can be prepared from biotin-NHS(N-hydroxysuccinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, 111.) and immobilized in the wells of streptavidin-coated 96 well plates (Pierce
- antibodies which specifically bind to a glutamate receptor delta-1 subunit polypeptide, polynucleotides, or a test compound, but which do not interfere with a desired binding site, such as the active site of the glutamate receptor delta-1 subunit polypeptide, can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.
- Methods for detecting such complexes include immunodetection of complexes using antibodies which specifically bind to a glutamate receptor delta-1 subunit polypeptide or test compound, enzyme-linked assays which rely on detecting a glutamate receptor delta-1 subunit activity of the glutamate receptor delta-1 subunit polypeptide, and SDS gel electrophoresis under non-reducing conditions.
- Any cell which comprises a glutamate receptor delta-1 subunit polynucleotide or polypeptide can be used in a cell-based assay system.
- a glutamate receptor delta-1 subunit polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Either a primary culture or an established cell line, including cell lines such as the HCN-1A, HCN-2, CATH.a, Neuro-2a, and
- PC 12 (Clontech), can be used, can be used.
- An intact cell is contacted with a test compound. Binding of the test compound to a glutamate receptor delta-1 subunit polypeptide or polynucleotide is determined as described above, after lysing the cell to release the glutamate receptor delta-1 subunit polypeptide-or polynucleotide-test compound complex.
- Test compounds can be tested for the ability to increase or decrease an activity of a human glutamate receptor delta-1 subunit polypeptide, such as ligand gated ion channel activity. Such activity is measured as is known in the art, for example, before and after contacting either a purified glutamate receptor delta-1 subunit polypeptide, a cell extract, or an intact cell with a test compound.
- a test compound which decreases glutamate receptor delta-1 subunit binding to a ligand, such as kainate, by at least about 10, preferably about 50, more preferably about 75, -90, or 100% is identified as a potential antagonist of the receptor;
- a test compound which increases glutamate receptor delta-1 subunit binding to the ligand by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential agonist of the receptor.
- test compounds which increase or decrease glutamate receptor delta-1 subunit gene expression are identified.
- a glutamate receptor delta-1 subunit polynucleotide is contacted with a test compound, and the expression of an RNA or polypeptide product of the glutamate receptor delta-1 subunit polynucleotide is determined.
- the level of expression of glutamate receptor delta-1 subunit mRNA or polypeptide in the presence of the test compound is compared to the level of expression of glutamate receptor delta-1 subunit mRNA or polypeptide in the absence of the test compound.
- the test compound can then be identified as a modulator of expression based on this comparison.
- polypeptide products of a glutamate receptor delta-1 subunit polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry.
- polypeptide synthesis can be determined in vivo, in a cell culture, or in an in vitro translation system by detecting incorporation of labeled amino acids into a glutamate receptor delta-1 subunit polypeptide.
- Such screening can be carried out either in a cell-free assay system or in an intact cell.
- Any cell which expresses a glutamate receptor delta-1 subunit polynucleotide can be used in a cell-based assay system.
- the glutamate receptor delta-1 subunit polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above.
- Either a primary culture or an established cell line, including cell lines such as the HCN-1A, HCN-2, CATH.a, Neuro-2a, and PC 12 (Clontech), can be used.
- compositions of the invention can comprise, for example, a glutamate receptor delta-1 subunit polypeptide, Glutamate receptor delta-1 subunit polynucleotide, antibodies which specifically bind to glutamate receptor delta-1 subunit activity, or mimetics, agonists, antagonists, or inhibitors of glutamate receptor delta-1 subunit activity.
- the compositions can be administered alone or in combination with at least one other agent, such as stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.
- compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.
- these pharmaceutical compositions can contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
- Pharmaceutical compositions of the invention can be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means.
- Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
- compositions for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen.
- disintegrating or solubilizing agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
- Dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.
- Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol.
- Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers.
- a filler or binders such as lactose or starches
- lubricants such as talc or magnesium stearate
- stabilizers optionally, stabilizers.
- the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
- compositions suitable for parenteral administration can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline.
- Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
- suspensions of the active compounds can be prepared as appropriate oily injection suspensions.
- Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- Non-lipid polycationic amino polymers also can be used for delivery.
- the suspension also can contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- compositions of the present invention can be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
- the pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.
- the preferred preparation can be a lyophilized powder which can contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.
- compositions After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.
- Glutamate is involved in epileptogenesis. Overstimulation of glutamate receptors can lead to seizures and excitotoxin injury throughout the CNS and in particular the hippocampus. Antagonists of glutamate receptor delta-1 subunit can act to prevent or treat epilepsy.
- Glutamate plays a role in ischemic brain damage and compounds that decrease the accumulation of glutamate or block its postsynaptic effects can ameliorate ischemic injury and other forms of acute neuronal degenerative diseases like hypoxia/hypoglycemia, traumatic brain injury, and stroke.
- Antagonists of glutamate receptor delta-1 subunit can act to prevent or treat brain damage.
- Excitotoxicity the overstimulation of glutamate receptors resulting in the death of neurons, participates in the pathogenesis of chronic neurodegenerative disorders including Huntington's disease, Alzheimer's disease, and Parkinson's disease.
- Antagonists of glutamate receptor delta-1 subunit can act to prevent or treat excitotoxicity and therefore can prevent or treat chronic neurodegenerative disorders.
- the excitatory amino acids glutamate and aspartate have been implicated in the transmission of acute and chronic pain. Blocking the activity of glutamate receptor delta-1 subunit can prevent or treat pain, and in particular chronic pain disorders. Pain which can be treated includes that which arises from pancreatitis, interstitial cystitis from various origin, including infection, dysfunctional bladder epithelium, neurogenic disturbances, bladder mastocytosis, allergic/immune/auto-immune causes, endocrine, food intolerance, painful bladder disease causing suprapubic, urethral, or pelvic pain, including interstitial cystitis, endometriosis, bacterial cystitis, outlet obstruction, dysmenorrhea, IBS (Irritable Bowel Syndrome), and Crohn's Disease, as well as pain syndromes of the pelvic cavity, e.g.
- Neuropathologic pain includes that arising in connection with multiple sclerosis, spinal cord injury, sciatica, failed back surgery syndrome, traumatic brain injury, epilepsy, Parkinson's disease, post-stroke status, vascular lesion in the brain and spinal cord, including infarct, hemorrhage, and vascular malformation.
- post mastectomy pain reflex sympathetic dystrophy (RSD), trigeminal neuralgia, radioculopathy, post-surgical pain, HIV/AIDS related pain, cancer pain, metabolic neuropathies (e.g., diabetic neuropathy), vasculitic neuropathy (e.g., secondary to connective tissue disease), paraneoplastic polyneuropathy associated e.g.
- Headache including migraine with aura, migraine without aura, episodic and chronic tension-type headache, cluster headache, and chronic paroxysmal hemicrania, as well as hyperirritability of the tracheobronchial tree, can be treated by regulating human glutamate receptor delta-1 subunit activity.
- dementias including Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia including Pick's disease, Parkinsonism, progressive nuclear palsy, corticobasal degeneration, motoneuron disease dementia, including ALS, Huntington's disease, multiple sclerosis, small-vessel cerebrovascular disease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia with dementia, and Korsakoff s psychosis can be treated.
- This invention further pertains to the use of novel agents identified by the screening assays described above. Accordingly, it is within the scope of this invention to use a test compound identified as described herein in an appropriate animal model.
- an agent identified as described herein e.g., a modulating agent, an antisense nucleic acid molecule, a specific antibody, ribozyme, or a polypeptide-binding partner
- an agent identified as described herein can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent.
- an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent.
- this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.
- a liposome is between about 100 and 500 ran, more preferably between about 150 and 450 nm, and even more preferably between about 200 and 400 nm in diameter.
- Suitable liposomes for use in the present invention include those liposomes standardly used in, for example, gene delivery methods known to those of skill in the art. More preferred liposomes include liposomes having a polycationic lipid composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol.
- a liposome comprises a compound capable of targeting the liposome to a tumor cell, such as a tumor cell ligand exposed on the outer surface of the liposome. Complexing a liposome with a reagent such as an antisense oligonucleotide or ribozyme can be achieved using methods which are standard in the art (see, for example, U.S. Patent 5,705,151).
- polynucleotide is combined with about 8 nmol of liposomes, more preferably from about 0.5 ⁇ g to about 5 ⁇ g of polynucleotides are combined with about 8 nmol liposomes, and even more preferably about 1.0 ⁇ g of polynucleotides is combined with about 8 nmol liposomes.
- antibodies can be delivered to specific tissues in vivo using receptor-mediated targeted delivery.
- Receptor-mediated DNA delivery techniques are taught in, for example, Findeis et al Trends in Biotechnol 11, 202-05 (1993); Chiou et al, GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER (J.A. Wolff, ed.) (1994); Wu & Wu, J. Biol. Chem. 263, 621-24 (1988); Wu et al, J. Biol. Chem. 269, 542-46 (1994); Zenke et al, Proc. Natl. Acad. Sci.
- a polynucleotide encoding the antibody can be constructed and introduced into a cell either ex vivo or in vivo using well- established techniques including, but not limited to, transferrin-polycation-mediated
- DNA transfer transfection with naked or encapsulated nucleic acids, liposome- mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun,” and DEAE- or calcium phosphate-mediated transfection.
- Effective in vivo dosages of an antibody are in the range of about 5 ⁇ g to about 50 ⁇ g/kg, about 50 ⁇ g to about 5 mg/kg, about 100 ⁇ g to about 500 ⁇ g/kg of patient body weight, and about 200 to about 250 ⁇ g/kg of patient body weight.
- effective in vivo dosages are in the range of about 100 ng to about 200 ng, 500 ng to about 50 mg, about 1 ⁇ g to about 2 mg, about 5 ⁇ g to about 500 ⁇ g, and about 20 ⁇ g to about 100 ⁇ g of DNA.
- the reagent is preferably an antisense oligonucleotide or a ribozyme.
- Polynucleotides which express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above.
- any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents.
- Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles.
- the combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
- a therapeutically effective dose refers to that amount of active ingredient which increases or decreases glutamate receptor delta-1 subunit binding activity relative to glutamate receptor delta-1 subunit binding activity which occurs in the absence of the therapeutically effective dose.
- the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs.
- the animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
- Therapeutic efficacy and toxicity e.g., ED 50 (the dose therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals.
- the dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD 50 /ED5o.
- compositions which exhibit large therapeutic indices are preferred.
- the data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use.
- the dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED5 0 with little or no toxicity.
- the dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
- the exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect. Factors which can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.
- Normal dosage amounts of any particular reagent can vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration.
- Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for polypeptides or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.
- any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.
- the polynucleotide of SEQ ID NO: 12 is inserted into the expression vector pCEV4 and the expression vector pCEV4-glutamate receptor delta-1 subunit polypeptide obtained is transfected into human embryonic kidney 293 cells.
- Binding reaction mixtures are incubated for one hour at 30 °C.
- the reaction is stopped by filtration through GF/B filters treated with 0.5% polyethyleneimine, using a cell harvester. Radioactivity is measured by scintillation counting, and data are analyzed by a computerized non-linear regression program.
- Non-specific binding is defined as the amount of radioactivity remaining after incubation of membrane protein in the presence of 100 nM of unlabeled peptide. Protein concentration is measured by the Bradford method using Bio-Rad Reagent, with bovine serum albumin as a standard. It is shown that the polypeptide of SEQ ID NO: 1
- the Pichia pastoris expression vector pPICZB (Invitrogen, San Diego, CA) is used to produce large quantities of a recombinant human glutamate receptor delta-1 subunit in yeast.
- the encoding DNA sequence is derived from the nucleotide sequence shown in SEQ ID NO:9, 10, 11 or 12.
- the DNA sequence is modified by well known methods in such a way that it contains at its 5 '-end an initiation codon and at its 3 '-end an enterokinase cleavage site, a His6 reporter tag, and a termination codon. Moreover, at both termini recognition sequences for restriction endonucleases are added.
- the modified DNA sequence is ligated into pPICZB.
- This expression vector is designed for inducible expression in Pichia pastoris, driven by a yeast promoter.
- the resulting pPICZ/md-His6 vector is used to transform the yeast.
- the yeast is cultivated under usual conditions in 5 liter shake flasks, and the recombinantly produced protein isolated from the culture by affinity chromatography
- Glutamate receptor delta-1 subunit polypeptides comprising a glutathione-S- transferase protein and absorbed onto glutathione-derivatized wells of 96-well microtiter plates are contacted with test compounds from a small molecule library at pH 7.0 in a physiological buffer solution.
- Glutamate receptor delta-1 subunit polypeptides comprise an amino acid sequence shown in SEQ ID NO:5, 6, 7, or 8.
- the test compounds comprise a fluorescent tag. The samples are incubated for 5 minutes to one hour. Control samples are incubated in the absence of a test compound.
- the buffer solution containing the test compounds is washed from the wells. Binding of a test compound to a glutamate receptor delta-1 subunit polypeptide is detected by fluorescence measurements of the contents of the wells. A test compound which increases the fluorescence in a well by at least 15% relative to fluorescence of a well in which a test compound was not incubated is identified as a compound which binds to a glutamate receptor delta-1 subunit polypeptide.
- a human embryonic 293 kidney cell line is transfected with a glutamate receptor delta-1 subunit polynucleotide.
- Test compounds comprising potential glutamate receptor delta-1 subunit antagonists or agonists are prepared. Forty-eight hours after transfection, agonist-activated and antagonist-deactivated currents in the presence of various ligands, such as kainate, are measured using standard patch clamp techniques in the whole-cell configuration. See Sommers et al. EMBO J. 11, 1651-1656, 1992;
- Keinanen et al Science. 249, 556-560 (1990); Sommer et al, Science. 249, 1580-1585; Verdoorn et al, Science. 252, 1715-1718, 1991.
- Currents in the presence of a test agonist or antagonist and in the absence of a test compound are collected, recorded and analyzed.
- Test compounds that evoke currents in the presence of the ligand are identified as agonists of glutamate receptor delta-1 subunit and compounds that depress currents in the presence of the ligand are identified as antagonists of glutamate receptor delta-1 subunit.
- oligonucleotides comprising at least 11 contiguous nucleotides selected from SEQ ID NO:9, 10, 11 or 12 is performed on a Pharmacia Gene Assembler series synthesizer using the phosphoramidite procedure (Uhlmann et al, Chem. Rev. 90, 534-83, 1990). Following assembly and deprotection, oligonucleotides are ethanol-precipitated twice, dried, and suspended in phosphate-buffered saline (PBS) at the desired concentration. Purity of these oligonucleotides is tested by capillary gel electro- phoreses and ion exchange HPLC. Endotoxin levels in the oligonucleotide preparation are determined using the Limulus Amebocyte Assay (Bang, Biol. Bull. (Woods Hole, Mass.) 105, 361-362, 1953).
- the antisense oligonucleotides are administered to a patient with epilepsy.
- the severity of the patient's epilepsy is decreased.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001279745A AU2001279745A1 (en) | 2000-07-18 | 2001-07-13 | Regulation of human glutamate receptor delta-1 subunit |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21883500P | 2000-07-18 | 2000-07-18 | |
US60/218,835 | 2000-07-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002006313A2 true WO2002006313A2 (en) | 2002-01-24 |
WO2002006313A3 WO2002006313A3 (en) | 2003-10-09 |
Family
ID=22816696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/008102 WO2002006313A2 (en) | 2000-07-18 | 2001-07-13 | Regulation of human glutamate receptor delta-1 subunit |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001279745A1 (en) |
WO (1) | WO2002006313A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001054477A2 (en) * | 2000-01-25 | 2001-08-02 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001077174A2 (en) * | 2000-04-06 | 2001-10-18 | Incyte Genomics, Inc. | Human transporters and ion channels |
-
2001
- 2001-07-13 WO PCT/EP2001/008102 patent/WO2002006313A2/en active Application Filing
- 2001-07-13 AU AU2001279745A patent/AU2001279745A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001054477A2 (en) * | 2000-01-25 | 2001-08-02 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001077174A2 (en) * | 2000-04-06 | 2001-10-18 | Incyte Genomics, Inc. | Human transporters and ion channels |
Non-Patent Citations (4)
Also Published As
Publication number | Publication date |
---|---|
AU2001279745A1 (en) | 2002-01-30 |
WO2002006313A3 (en) | 2003-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030171324A1 (en) | Regulation of human desc1-like serine protease | |
US20030003488A1 (en) | Regulation of human mitochondrial deformylase | |
WO2002022631A2 (en) | Regulation of human pyroglutamyl peptidase-like enzyme | |
US20040030099A1 (en) | Regulation of human patched-like protein | |
US20030186919A1 (en) | Regulation of human sodium-dependent monoamine transporter | |
WO2001092310A2 (en) | Regulation of human transketolase-like enzyme | |
WO2002006313A2 (en) | Regulation of human glutamate receptor delta-1 subunit | |
US20030099982A1 (en) | Regulation of human glur5 -like receptor | |
WO2002033080A2 (en) | Regulation of human netrin binding membrane receptor unc5h-1 | |
US20030175941A1 (en) | Regulation of human serine racemase enzyme | |
WO2001072833A2 (en) | Human ephrin-like receptor | |
WO2001090160A2 (en) | REGULATION OF HUMAN p78-LIKE SERINE/THREONINE KINASE | |
WO2001070813A2 (en) | REGULATION OF HUMAN GluR5-LIKE RECEPTOR | |
WO2001090318A2 (en) | Regulation of human polyamine oxidase-like enzyme | |
US20040029247A1 (en) | Regulation of human adenylate cyclase, type iv | |
WO2001072955A2 (en) | Regulation of human nedd1-related protein | |
WO2002029049A2 (en) | Regulation of human sodium-dependent monoamine transporter | |
EP1272521A2 (en) | Regulation of human oatp2-related protein | |
WO2002046403A2 (en) | Regulation of human patched-like protein | |
WO2001073017A2 (en) | Regulation of human adp-ribosylation factor-related protein | |
EP1272646A2 (en) | Regulation of human serine racemase enzyme | |
US20030049670A1 (en) | Regulation of human leucine aminopeptidase-like enzyme | |
WO2002038761A2 (en) | Regulation of human oat-like protein | |
WO2001068840A2 (en) | REGULATION OF HUMAN DIAZEPAM BINDING INHIBITOR/ACYL-CoA-LIKE PROTEIN | |
WO2001068841A2 (en) | Human dcc-like proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase in: |
Country of ref document: RU Kind code of ref document: A Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |